Arousal problems usually have a cause that can be found, such as menopause-related tissue changes, a medication, or stress and relationship strain. Vaginal estrogen has strong evidence when dryness or pain is driving the problem, while testosterone and bremelanotide (PT-141) have narrower, mostly off-label roles. The right plan starts with an evaluation that separates desire, arousal and pain.
Female sexual arousal disorder is treated by first finding what is blunting the body's response, then matching care to that cause. Hormone options, mainly vaginal estrogen and in narrower cases testosterone, help when menopause-related tissue changes are the driver.
The peptide bremelanotide (PT-141) acts on brain pathways tied to desire, but its FDA approval covers low desire before menopause, not arousal problems on their own.
This guide walks through how arousal differs from desire, what tends to cause it, how each hormone and peptide option fits, and the honest limits of the evidence. It is written for women who want to understand their options before a visit, not to replace one.
Arousal, Desire and Orgasm: Why the Distinction Matters
Desire is the wish for sexual connection. Arousal is the response that follows: lubrication, genital swelling, sensation and the feeling of being turned on. Many women still want closeness but notice that the body no longer keeps up.
The psychiatric manual used for diagnosis, the DSM-5, now groups low desire and low arousal together as female sexual interest/arousal disorder. A review in Women's Health explains that symptoms must last at least six months and cause real distress to meet that definition.
In everyday care, the separation still matters. A desire problem and a tissue problem can feel similar, yet they respond to different treatments. Our page on female sexual arousal disorder covers the condition itself; this article focuses on the treatment options.
What Usually Sits Behind Arousal Problems
Arousal depends on hormones, blood flow, nerves, healthy tissue and a nervous system that feels safe enough to relax. When one of those links weakens, response slows. More than one factor is often present at the same time.
Common contributors include:
Menopause and perimenopause. Falling estrogen thins and dries vaginal tissue, which can make arousal slower and sex uncomfortable.
Medications. Antidepressants in the SSRI class carry a high risk of sexual side effects, according to the same Women's Health review.
Pain and guarding. Dryness can lead to pain, and pain can trigger a reflex tightening of the pelvic floor muscles that makes arousal even harder.
Stress, mood and relationship strain. A body on high alert protects first, and intimacy is often where that shows up.
Health conditions that affect blood vessels or nerve signaling.
When stress, mood or the relationship is the main driver, counseling or sex therapy can matter as much as any prescription. A good provider will say so rather than reaching for a hormone first.
Hormone Options and What the Evidence Shows
Hormones are the most studied part of this picture, but each one has a specific job. Estrogen mainly supports the tissue. Testosterone has its best evidence for desire, not arousal alone. Knowing that difference keeps expectations realistic.
Vaginal estrogen for tissue-driven arousal problems
When arousal trouble comes with dryness, irritation or pain, the root cause is often the genitourinary syndrome of menopause. The North American Menopause Society's 2020 position statement estimates it affects roughly 27% to 84% of postmenopausal women and is likely underdiagnosed.
The same statement concludes that low-dose vaginal estrogen is an effective treatment for moderate to severe symptoms. Because only a small amount is absorbed, it works on the tissue rather than the whole body. When comfort and lubrication return, arousal often becomes easier too.
Systemic hormone therapy around menopause
For women who also have hot flashes, poor sleep or other menopause symptoms, systemic estrogen can treat several problems at once. It is listed among effective therapies in the same position statement. Our team approaches this through bioidentical hormone therapy guided by labs and follow-up.
Testosterone for women: a narrow, monitored role
Testosterone gets a lot of attention, and the evidence is more specific than most marketing suggests. The Global Consensus Position Statement on testosterone for women, endorsed by major menopause and endocrine societies, finds that the only evidence-based use is low sexual desire (HSDD) after menopause.
The panel found insufficient data for any other symptom. It also advises keeping blood levels within the normal female range and recommends against pellets or injections that push levels higher. Regular monitoring is part of safe use.
No testosterone product is FDA-approved for women's sexual concerns, so a prescription for a woman is off-label and should be dosed and monitored with that in mind.
Peptide Options: Where Bremelanotide (PT-141) Fits
Peptide-based care can open a different kind of discussion, especially when the concern centers on responsiveness and overall sexual function rather than tissue comfort. The best-studied option here is bremelanotide (PT-141), a melanocortin peptide that works through the brain instead of blood flow.

In two phase 3 trials published in Obstetrics and Gynecology, 1,247 premenopausal women with HSDD used bremelanotide as needed for 24 weeks. Compared with placebo, they reported statistically significant increases in desire and less distress. The average gains were modest, and nausea, flushing and headache were common.
Bremelanotide is FDA-approved, under the brand name Vyleesi, for low sexual desire in premenopausal women. That approval matters for how we talk about it.
Using bremelanotide for arousal problems alone, or after menopause, is off-label, and it does not treat dryness or tissue changes.
Other medicines you may hear about
Mayo Clinic's overview of treatment for female sexual dysfunction notes that sildenafil and related erectile dysfunction drugs have shown mixed results in women. It adds that sildenafil may help some women whose sexual side effects come from SSRI antidepressants.
The same overview describes ospemifene, a pill, and prasterone, a vaginal DHEA insert, as options for painful sex caused by thinning tissue. Flibanserin is a second FDA-approved pill for low desire before menopause.
How Long Before You Know Whether a Treatment Is Working
Each option has its own timeline, and agreeing on a check-in point up front keeps you from staying on something that is not helping.
Testosterone: the global consensus panel advises a blood level 3 to 6 weeks after starting and stopping treatment if there is no benefit by 6 months.
Flibanserin: Mayo Clinic notes that experts suggest stopping if desire has not improved after eight weeks.
Bremelanotide: it is used as needed before sex rather than daily, and the phase 3 trials judged results over 24 weeks.
Tissue-Focused Care as Part of the Plan
Some women have arousal problems because sex has become uncomfortable, not because desire has faded. In that case, improving the tissue comes first. Vaginal estrogen is one route.
When dryness, laxity after childbirth or reduced sensation is part of the pattern, a tissue-focused treatment such as radiofrequency vaginal rejuvenation may be discussed alongside hormone care. It is one piece of a plan, never a substitute for finding the underlying cause.
The Options at a Glance
Vaginal estrogen: treats dryness, irritation and pain from menopause-related tissue change. Strong evidence for those symptoms.
Systemic hormone therapy: treats menopause symptoms broadly, including tissue changes. Chosen when other menopause symptoms are present too.
Testosterone: evidence supports it for low desire after menopause. Off-label for women in the US and needs monitoring.
Bremelanotide (PT-141): approved for low desire before menopause. Modest average benefit; off-label for arousal alone.
Sildenafil: mixed results in women; may help SSRI-related problems.
Counseling or sex therapy: often central when stress, mood or the relationship is the main driver.
What We Review Before Recommending Treatment
Our women's health care is led by Chief Medical Director Dr. Dawn Ericsson, MD, a board-certified OB/GYN. Before recommending anything, we sort out whether the main issue is desire, arousal, pain or a mix, because each points somewhere different.
That review usually covers:
What changed, when it started and whether it happens in every situation or only some
Current medications, including antidepressants and hormonal contraception
Menstrual and menopause history
Hormone labs, chosen to fit your symptoms
A gentle exam when dryness, pain or tissue change is suspected
Arousal difficulty often overlaps with other concerns covered under female sexual dysfunction, such as low desire, pain with sex or trouble reaching orgasm. Seeing the full pattern is what keeps a plan specific to you.
Questions Worth Asking Your Provider
These questions help you judge any recommendation, wherever you are treated:
Do you think my main problem is desire, arousal, pain or a combination?
Could any of my current medications be contributing?
Is this treatment FDA-approved for my situation, or would it be off-label?
What does the research show for women like me, and how large is the typical benefit?
What side effects should I watch for, and how will we monitor them?
How will we know if it is working, and when would we change course?
Where to Start
We see women at our clinics in South Tampa, Brandon, Wesley Chapel, Winter Garden and Orlando, so follow-up visits can fit around work and family. You can find addresses and hours on our locations page.
Arousal changes are common, and they are a medical concern worth raising, not something you have to accept. A careful first conversation is usually the most useful step.

Frequently Asked Questions
Is there a medication approved specifically for female arousal disorder?
Not specifically. The two FDA-approved medicines for women's sexual concerns, flibanserin and bremelanotide, are approved for low sexual desire before menopause. When arousal problems come from tissue changes, vaginal estrogen and related treatments for menopause symptoms address the cause more directly.
Does PT-141 help with arousal or only with desire?
Bremelanotide was studied and approved for low desire and the distress it causes. Because desire and arousal overlap, some women notice changes in both, but the trial evidence centers on desire. Using it mainly for arousal is off-label, and it will not fix dryness or discomfort.
Can low testosterone cause arousal problems in women?
Testosterone plays a role in women's sexual function, but the global consensus panel found that no blood level separates women with and without sexual problems. Current consensus supports testosterone only for low desire after menopause, dosed within the normal female range. Arousal problems driven by dryness or pain usually respond better to estrogen-based care.
Is female sexual arousal disorder permanent?
For many women it is not. When the driver is a medication, menopause-related tissue change or a treatable health issue, addressing that cause often improves response. Progress varies from person to person, and some women do best combining medical care with counseling.
How do I bring this up with a provider?
It is enough to say that intimacy has changed and you want to understand why. Describing what you notice, such as slower lubrication, less sensation or pain, gives your provider a clear starting point. You do not need the medical term to ask for help.
Sources
Basson R, Gilks T. Women's sexual dysfunction associated with psychiatric disorders and their treatment. Women's Health. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5900810/
The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. https://pubmed.ncbi.nlm.nih.gov/32852449/
Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6821450/
Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019. https://pubmed.ncbi.nlm.nih.gov/31599840/
Mayo Clinic. Female sexual dysfunction: Diagnosis and treatment. https://www.mayoclinic.org/diseases-conditions/female-sexual-dysfunction/diagnosis-treatment/drc-20372556
Ready to take the next step?
Talk with the AgeRejuvenation team about a Hormone Replacement Therapy plan built around your labs and goals.